Key result
Stopping clopidogrel in stable CAD or PAD shows no rebound platelet activity versus placebo.
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our findings provide reassurance for doctors that they can safely halt therapy using clopidogrel in patients that are stable, as per current guidelines, without leading to a rebound in platelet activity.”
“Our trial recruited 171 patients who had narrowed arteries in their heart or leg arteries. They were given clopidogrel and aspirin, or a placebo capsule and aspirin, to take for one month. We measured blood platelet activity using a range of tests before, during treatment, and after stopping the medicine.”
Randomized trial evaluates platelet activity before and after clopidogrel cessation in stable cardiovascular disease, highlighting recovery dynamics.
RCT (n=171)
placebo-controlled
randomly assigned
p-value: p=> 0.05
Ford et al. (2013) conducted an RCT in stable coronary artery or peripheral arterial disease (n=171). Clopidogrel vs. Placebo was evaluated on adenosine diphosphate (ADP)-stimulated platelet fibrinogen binding (p=> 0.05). Stopping clopidogrel therapy in patients with stable coronary or peripheral arterial disease showed no evidence of rebound platelet activity compared with placebo (p > 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: